

DAFTAR PUSTAKA

1. Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: A global health crisis. *Cancer*. 2017;123(13):1–9.
2. Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. *Chinese J Cancer Res*. 2020;32(6):1–9.
3. World Health Organization. All Cancers - Global Cancer Observatory. Vol. 419. 2020.
4. World Health Organization. Cervix Uteri - Global Cancer Observatory. Vol. 419. 2021.
5. World Health Organization. Europe - Global Cancer Observatory. Vol. 086. 2021.
6. World Health Organization. Germany - Global Cancer Observatory. Vol. 697. 2020.
7. World Health Organization. Netherlands - Global Cancer Observatory. Vol. 015. 2021.
8. World Health Organization. United States of America - Global Cancer Observatory. Vol. 465. 2021.
9. World Health Organization. Asia - Global Cancer Observatory. Vol. 136. 2021.
10. World Health Organization. Singapore - Global Cancer Observatory. Vol. 662. 2021.
11. World Health Organization. Malaysia - Global Cancer Observatory. Vol. 418. 2021.
12. World Health Organization. Indonesia - Global Cancer Observatory. Vol. 858. 2021.

13. Gondhowiardjo SA, Kusumadjati A, Wibisono P, Sekarutami SM. Cervical Cancer Profile in dr. Cipto Mangunkusumo Hospital Year 2013. *Radioter Onkol Indones.* 2019;10(1):1–7.
14. Okunade KS. Human papillomavirus and cervical cancer. *J Obstet Gynaecol (Lahore).* 2020;40(5):1–7.
15. Bernal Aguirre LE, Mongelós-Dacunte PE, Alfonzo Salinas TM, Cardozo F, Mendoza Torres LP. Optimization of a conventional PCR technique for detection of human papillomavirus type 16 and 18. *Proc Heal Sci Res Inst.* 2018;16(3):6–12.
16. Vet JNI, De Boer MA, Van Den Akker BEWM, Siregar B, Lisnawati, Budiningsih S, et al. Prevalence of human papillomavirus in Indonesia: A population-based study in three regions. *Br J Cancer.* 2008;99(1):214–8.
17. Fowler JR, Maani E V., Jack BW. Cervical Cancer. *Encycl Behav Med.* 2021 Jul 7;350–1.
18. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. *Lancet Glob Heal.* 2021;9(2):161–9.
19. Liu ZC, Liu WD, Liu YH, Ye XH, Chen SD. Multiple sexual partners as a potential independent risk factor for cervical cancer: A meta-analysis of epidemiological studies. *Asian Pacific J Cancer Prev.* 2015;16(9):3893–900.
20. Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer—A systematic review & meta-analysis. *Eur J Obstet Gynecol Reprod Biol.* 2020;247:163–75.
21. Kim G. Harald zur Hausen. *Embryo Proj Encycl.* 2017;349(9055):890.
22. Mac M, Moody CA. Epigenetic regulation of the human papillomavirus life cycle. *Pathogens.* 2020;9(6):1–18.
23. Wendland EM, Horvath JDC, Kops NL, Bessel M, Caierão J, Hohenberger

- GF, et al. Sexual behavior across the transition to adulthood and sexually transmitted infections Findings from the national survey of human papillomavirus prevalence (POP-Brazil). *Med (United States)*. 2018;97(33).
24. Petca A, Borislavski A, Zvanca M, Petca R-C, Sandru F, Dumitrascu M. Non-sexual HPV transmission and role of vaccination for a better future (Review). *Exp Ther Med*. 2020;20(6):1–5.
 25. Moody CA. Mechanisms by which HPV induces a replication competent environment in differentiating keratinocytes. *Viruses*. 2017;9(9).
 26. Gustavsson I, Aarnio R, Myrnäs M, Hedlund-Lindberg J, Taku O, Meiring T, et al. Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening. *Virol J*. 2019;16(1):1–7.
 27. Bennett KM. Molecular Testing for Human Papillomaviruses. *Diagnostic Mol Pathol*. 2017;75–87.
 28. Jenkins D, Xavier Bosch F. Human papillomavirus: Proving and using a viral cause for cancer. *Human Papillomavirus: Proving and Using a Viral Cause for Cancer*. 2019. 85–106 p.
 29. Colyar MA. *Advanced Practice Nursing Procedures Second Edition*. 2020.
 30. Institute for Quality and Efficiency in Health Care (IQWiG). *Hysterectomy (surgical removal of the womb)*. 2018;
 31. Alrajjal A, Pansare V, Choudhury MSR, Khan MYA, Shidham VB. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. *Cytojournal*. 2021 Jul 17;18:16.
 32. Kumar V, Abbas A, Aster J, Perkins J. *Robbins Basic Pathology*. 10th ed. Elsevier; 2018. 717–721 p.
 33. Robboy SJ, Mutter GL, Prat J, Bentley RC, Russel P, Anderson MC.

- Robboy's Pathology of the Female Reproductive Tract. 2nd ed. Vol. 4, Human Fertility. 2009. 191 p.
34. NCI Dictionary of Cancer Terms. Definition of cervical cancer. National Cancer Institute. 2021.
 35. The American Cancer Society medical and editorial content team. What Is Cervical Cancer? | Types of Cervical Cancer. American Cancer Society. 2020.
 36. Kemenkes RI. Mengenal Kanker Leher Rahim - Direktorat P2PTM. 2019.
 37. Xing B, Guo J, Sheng Y, Wu G, Zhao Y. Human Papillomavirus-Negative Cervical Cancer: A Comprehensive Review. *Front Oncol.* 2021;10:1–8.
 38. Jenkins D, Molijn A, Kazem S, Pirog EC, Alemany L, de Sanjosé S, et al. Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study. *Int J Cancer.* 2020;147(9):2526–36.
 39. Ghittoni R, Accardi R, Chiocca S, Tommasino M. Role of human papillomaviruses in carcinogenesis. *Ecancermedicallscience.* 2015;9:1–9.
 40. Quinn BA, Deng X, Colton A, Bandyopadhyay D, Carter JS, Fields EC. Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival. *Brachytherapy.* 2019;18(1):29–37.
 41. Kong Y, Zong L, Yang J, Wu M, Xiang Y. Cervical cancer in women aged 25 years or younger: A retrospective study. *Cancer Manag Res.* 2019;11:2051–8.
 42. Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the development of cervical cancer? *Transl Res.* 2017;179:168–82.
 43. IARC. Personal habits and indoor combustions. IARC Monogr Eval Carcinog risks to humans. 2012;100:319–31.
 44. Sugawara Y, Tsuji I, Mizoue T, Inoue M, Sawada N, Matsuo K, et al. Cigarette smoking and cervical cancer risk: An evaluation based on a

- systematic review and meta-analysis among Japanese women. *Jpn J Clin Oncol.* 2019;49(1):77–86.
45. Kashyap N, Krishnan N, Kaur S, Ghai S. Risk Factors of Cervical Cancer: A Case-Control Study. *Asia-Pacific J Oncol Nurs.* 2019;6(3):308–14.
 46. Schiffman M, Doorbar J, Wentzensen N, De Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. *Nat Rev Dis Prim.* 2016;2.
 47. Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. *PLoS Pathog.* 2020;16(3):1–20.
 48. IARC. WHO Classification of Female Genital Tumours. 5th ed. 2020. 335–390 p.
 49. Komite Penanggulangan Kanker Nasional. Panduan Penatalaksanaan Kanker Serviks. 2017;
 50. Komite Penanggulangan Kanker Nasional. Pedoman Nasional Pelayanan Kedokteran Kanker Serviks. 2017;
 51. IARC. Human Papillomavirus and Related Cancers, Fact Sheet 2021. Information Centre on HPV and Cancer. 2021.
 52. Mahendra INB. The Characteristics of Cervical Cancer Patients Who Underwent a Radical Hysterectomy at Sanglah Hospital Denpasar in 2015. *Bali Med J.* 2016;5(2):48.
 53. Oyervides-Muñoz MA, Pérez-Maya AA, Sánchez-Domínguez CN, Berlanga-Garza A, Antonio-Macedo M, Valdéz-Chapa LD, et al. Multiple HPV infections and viral load association in persistent cervical lesions in Mexican women. *Viruses.* 2020;12(4).
 54. Sundström K, Ploner A, Arnheim-Dahlström L, Eloranta S, Palmgren J, Adami HO, et al. Interactions between High- and Low-Risk HPV Types

- Reduce the Risk of Squamous Cervical Cancer. *J Natl Cancer Inst.* 2015;107(10):1–7.
55. Hasanzadeh M, Rejali M, Mehramiz M, Akbari M, Mousavi Seresht L, Yazdandoost Y, et al. The interaction of high and low-risk human papillomavirus genotypes increases the risk of developing genital warts: A population-based cohort study. *J Cell Biochem.* 2019;120(8):1–5.
56. Mastutik G, Rahniayu A, Kurniasari N, Rahaju AS, Harjanto B. Distribution of Human Papilloma Virus (HPV) in Cervical Adenocarcinoma and Adenosquamous Carcinoma. *Folia Medica Indones.* 2021;57(2):170.
57. Hardjolukito WL. Hubungan antara Genotyping DNA Human Pappillomavirus (HPV) dengan Respons Terapi Radiasi pada Adenokarsinoma Serviks. *Indones J Cancer.* 2015 Mar 31;9(1):13–22.
58. Risnawati, Soejoenoes A, Hadisaputro S, Sofro MA, Djauzi S, Pramono N, et al. Hpv 52 most dominant human papillomavirus (Hpv) genotype in women infected by human immunodeficiency virus (hiv) that get antiretroviral treatment (art). *Int J Pharm Res.* 2020 Oct 1;12(4):2568–73.
59. Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. *J Low Genit Tract Dis.* 2020;24(2):132–43.
60. Liu Y, Ang Q, Wu H, Xu J, Chen D, Zhao H, et al. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: Analysis of results from China’s top 3 hospital, 2009-2019. *Virol J.* 2020;17(1):1–10.
61. Bruno MT, Cassaro N, Bica F, Boemi S. Progression of CIN1/LSIL HPV Persistent of the Cervix: Actual Progression or CIN3 Coexistence. *Infect Dis Obstet Gynecol.* 2021;